AstraZeneca Pharmaceuticals LP
NEWS
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
The company is presenting the study of Tagrisso during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Sunday, May 31.
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
The U.S. Biomedical Advanced Research and Development Authority (BARDA) paid more than $1 billion to support the development, production and delivery of the vaccine beginning this fall.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.
JOBS
IN THE PRESS